Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial
Sandra Heesch(BioNTech (Germany)), Uğur Şahin(Johannes Gutenberg University Mainz), Andreas N. Kuhn(Uppsala University Hospital), Sebastian Kreiter(Johannes Gutenberg University Mainz), Tobias Sjöblom(Uppsala University), Alexandra Kemmer-Brueck(BioNTech (Germany)), Klaus Kuehlcke, K Schultheiß(BioNTech (Germany)), Anna Paruzynski(BioNTech (Germany)), Marcus Schmidt(Johannes Gutenberg University Mainz), Thomas Kuendig(University Hospital Zurich), Henrik Lindman(Uppsala University), Doreen Schwarck(BioNTech (Germany)), Heinrich Haas(BioNTech (Germany)), K Ewen(BioNTech (Germany)), Laurence Zitvogel(Institut Gustave Roussy), Martin Löewer(Uppsala University Hospital), Valesca Bukur(Uppsala University Hospital), Mustafa Diken, Björn‐Philipp Kloke(BioNTech (Germany)), Jacques De Grève(Vrije Universiteit Brussel), Jan Diekmann(BioNTech (Germany)), Steve Pascolo(University of Zurich), Kris Thielemans(Vrije Universiteit Brussel), Özlem Türeci(Johannes Gutenberg University Mainz), Janina Buck(BioNTech (Germany)), Fabrice André(Inserm)
Cited by 5
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
|Science|2006|3.2k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k